The Buzz: February 19, 2001

 
 
By eweek  |  Posted 2001-02-19 Email Print this article Print
 
 
 
 
 
 
 

Those interested in the ongoing battle between Microsoft and the U.S. Department of Justice can get an earful later this month.

Microsoft Case Goes to Audio

Those interested in the ongoing battle between Microsoft and the U.S. Department of Justice can get an earful later this month.

The U.S. Court of Appeals for the District of Columbia Circuit, which is overseeing the antitrust case, said it will provide live audio of the oral arguments in Microsofts appeal of last years lower-court order to break up the company.

The sides will argue the appeal Feb. 26 and 27. The audio will be available through a network pool of the media via live streaming audio over the Internet on www.c-span.org and www.abcnews.com.

Microsoft is accused of using anti-competitive practices to maintain a monopoly. The focus is on Windows and the Internet Explorer browser.

Clinton to Give Oracle Keynote

Hes been out of office for almost a month, but former President Clinton still seems to be everywhere. This week, hes going to be in New Orleans, giving the keynote speech at Oracles AppsWorld conference.

Since leaving the White House, Clinton has been awash in controversy, from his last-minute pardons to the price of his New York offices. When he gets to New Orleans, hes sure to run into his former press secretary, Joe Lockhart, who now runs Oracles communications office.

Clinton has commanded as much as $150,000 per engagement. Oracle officials declined to say how much theyre paying him but said it was in the range of previous appearances.

Dating, Drug Sites on Move

Last week, both dating and pharmaceutical online markets saw their numbers drop by one.

On Valentines Day, matchmaking site udate.com announced it was buying rival Kiss.com for $17.7 million. The move will give udate.com more than 3.3 million members.

PlanetRX.com stopped taking prescriptions and began referring customers to rival Drugstore.com.

The company said it will shift to the specialty drug market but will retain its name.

 
 
 
 
 
 
 
 
 
 
 

Submit a Comment

Loading Comments...
 
Manage your Newsletters: Login   Register My Newsletters























 
 
 
 
 
 
 
 
 
 
 
Rocket Fuel